TOPIC HIGHLIGHT

WJG 20th Anniversary Special Issues (6): *Helicobacter pylori*

Brain-gut axis in the pathogenesis of *Helicobacter pylori* infection

Jacek Budzyński, Maria Kłopocka

Jacek Budzyński, Department of Gastroenterology, Vascular Diseases and Internal Medicine, Nicolaus Copernicus University, The Ludwik Rydygier Collegium Medicum in Bydgoszcz, 85-168 Bydgoszcz, Poland
Jacek Budzyński, Clinical Ward of Vascular Diseases and Internal Medicine, The Jan Biziel University Hospital No. 2, 85-168 Bydgoszcz, Poland
Maria Kłopocka, Department of Gastroenterological Nursing, Nicolaus Copernicus University, The Ludwik Rydygier Collegium Medicum in Bydgoszcz, 85-168 Bydgoszcz, Poland
Author contributions: Budzyński J conceived of and wrote the manuscript; Kłopocka M revised the manuscript; Budzyński J and Kłopocka M performed the literature review, wrote the paper and approved the final revised version.
Correspondence to: Jacek Budzyński, MD, PhD, Clinical Ward of Vascular Diseases and Internal Medicine, The Jan Biziel University Hospital No. 2, Ujejskiego 75 Street, 85-168 Bydgoszcz, Poland. budz@cps.pl
Telephone: +48-52-3655347   Fax: +48-52-3655347
Received: September 25, 2013 Revised: January 11, 2014
Accepted: January 19, 2014
Published online: May 14, 2014

Abstract

Helicobacter pylori (*H. pylori*) infection is the main pathogenic factor for upper digestive tract organic diseases. In addition to direct cytotoxic and proinflammatory effects, *H. pylori* infection may also induce abnormalities indirectly by affecting the brain-gut axis, similar to other microorganisms present in the alimentary tract. The brain-gut axis integrates the central, peripheral, enteric and autonomic nervous systems, as well as the endocrine and immunological systems, with gastrointestinal functions and environmental stimuli, including gastric and intestinal microbiota. The bidirectional relationship between *H. pylori* infection and the brain-gut axis influences both the contagion process and the host's neuroendocrine-immunological reaction to it, resulting in alterations in cognitive functions, food intake and appetite, immunological response, and modification of symptom sensitivity thresholds. Furthermore, disturbances in the upper and lower digestive tract permeability, motility and secretion can occur, mainly as a form of irritable bowel syndrome. Many of these abnormalities disappear following *H. pylori* eradication. *H. pylori* may have direct neurotoxic effects that lead to alteration of the brain-gut axis through the activation of neurogenic inflammatory processes, or by microelement deficiency secondary to functional and morphological changes in the digestive tract. In digestive tissue, *H. pylori* can alter signaling in the brain-gut axis by mast cells, the main brain-gut axis effector, as *H. pylori* infection is associated with decreased mast cell infiltration in the digestive tract. Nevertheless, unequivocal data concerning the direct and immediate effect of *H. pylori* infection on the brain-gut axis are still lacking. Therefore, further studies evaluating the clinical importance of these host-bacteria interactions will improve our understanding of *H. pylori* infection pathophysiology and suggest new therapeutic approaches.

Core tip: This manuscript is the first review concerning the interplay between *Helicobacter pylori* (*H. pylori*) infection and the brain-gut axis. Data from relevant publications, including both human and animal studies, were grouped and discussed according to the pathophysiological mechanisms of interactions between *H. pylori* and host reaction.

Budzyński J, Kłopocka M. Brain-gut axis in the pathogenesis of *Helicobacter pylori* infection. *World J Gastroenterol* 2014; 20(18): 5212-5225 Available from: URL: http://www.wjgnet.com/1007-9327/full/v20/i18/5212.htm DOI: http://dx.doi.org/10.3748/wjg.v20.i18.5212

BRAIN-GUT AXIS AND *HELICOBACTER PYLORI*

Upper digestive tract diseases, including both functional dyspepsia and dyspeptic symptoms in the course of gastritis or peptic ulcers, were considered for many years to be psychosomatic[1,2]. However, *Helicobacter pylori* (*H. pylori*) infection has been recognized as the main risk factor for many upper digestive tract disorders and complications, including life-threatening bleeding from the digestive tract, gastritis, non-ulcer dyspepsia, mucosa-associated lymphoid tissue (MALT) lymphoma and gastric cancer[3,4], and a risk factor for stress-induced peptic ulcers[2,5-8]. As a result, the role of psychosomatic factors in the pathogenesis of these diseases has since lost favor[1,9]. However, the presence of *H. pylori*-negative upper digestive tract abnormalities, such as peptic ulcers[10,11], and the fact that not all *H. pylori*-infected patients develop ulcers, with only 10%-15% of them presenting dyspeptic symptoms[3], suggest a role for other individual factors, including nervous system imbalance, as an indispensable cofactor in gastritis or ulcer disease pathogenesis[12]. These arguments imply that *H. pylori* infection may induce changes in the function and morphology of the digestive tract both directly through cytotoxin (CagA, VacA) release and inflammatory process activation, and indirectly, *via* the brain-gut axis[13]. This review presents and discusses the interaction between *H. pylori* infection and the brain-gut axis and the clinical implications for digestive tract function.

The brain-gut axis is anatomically based in the central (CNS), peripheral (PNS, enteric nervous system, or "little brain"), and autonomic nervous systems (ANS), and modulates gastrointestinal function *via* the regulation of the gastrointestinal immune system, mucosal inflammation and intestinal microbiota in response to stress, emotions and environmental influences[6,14,15]. This circuitry acts bidirectionally, playing a role both in upper (peptic ulcer, functional dyspepsia) and lower [irritable bowel syndrome (IBS), inflammatory bowel disease (IBD)] digestive tract homeostasis, appetite and weight control[6,15-17], modulation of the gut-associated immune system and in the coordination of the gastrointestinal tract with the overall physical and emotional state of the organism[18]. However, so many interactions and functions work not only *via* the nervous system, but also through the endocrine, immunological and metabolic pathways (neuroendocrine-immune crosstalk)[6,15-22]. The main endocrine role is played by the hypothalamus-pituitary-adrenal (HPA) axis, along with the highly significant neuroendocrine-immune response modulator corticotropin releasing factor (CRF). CRF regulates inflammation, gut permeability, visceral hypersensitivity, gut motility and HPA axis activity, and is recognized as the major endocrine system response to stress[6,14,21-25].

Intestinal bacteria also play an important and proven role in the above-described relationships ("brain-gut-enteric microbiota axis," or "microbiome-gut-brain axis"), whose composition and function are related to

nervous system activity and, in turn, communicate with the brain-gut axis through endocrine, immunological and neural messages[6,18,20,26-28]. Such bidirectional interactions are suspected on the basis of the following observations: (1) stress and mental disorders have a harmful effect on digestive tract function and intestinal bacterial flora[5,6,29]; (2) patients with digestive tract disorders have a high prevalence of neuropsychological comorbidities, such as depression, anxiety and alexithymia[13]; (3) changes in cognitive function occur after diet-induced gut-dysbiosis[18] or with alimentary tract diseases (*e.g.*, hepatic encephalopathy) which may be altered after antibiotics, probiotics or laxative administration[15,30]; (4) patients with major depression show altered intestinal fermentation profiles[31]; (5) individuals with autism have abnormal microbiota and experience shorter antibiotic effects[32-34]; (6) some patients with digestive tract disorders demonstrate an ANS imbalance[6,14,15,21,22,29,35-39]; and (7) digestive tract stimulation and/or infection can produce abnormalities in brain-imaging techniques that show the activation (evoked potentials) or deactivation of specific brain regions, such as functional magnetic resonance imaging, positron emission tomography, magnetoencephalography and electroencephalography[40].

As a gastric mucosa-colonizing microorganism, *H. pylori* may contribute to the bidirectional nature of the brain-gut axis as evidenced by: (1) the overlapping of upper and lower digestive tract functional symptoms in *H. pylori* infected patients[18,41-43] and the effect of *H. pylori* infection on IBS symptoms[43] (but see Breckan *et al*[44]) and pancreatic juice secretion[45]; (2) the protection against IBD appearance by *H. pylori* infection[17,46] resulting from changes induced in brain-gut axis function (neuroendocrine-immune crosstalk)[6,15,21,22,26,47,48]; (3) the association of *H. pylori* infection with ANS-related extra-digestive diseases, such as atherosclerosis or cardiac arrhythmia[3,35]; (4) the improved physical and psychological health-related quality of life and sexual relationships after digestive tract symptom alleviation and *H. pylori* eradication[49,50]; (5) the proposed association between *H. pylori* infection and the development of axonal type Guillain-Barré neuropathy, multiple sclerosis and epilepsy[51-53], and case reports of gastric MALT lymphoma followed by primary CNS lymphoma[54]; and (6) the modulation of ANS balance by *H. pylori* infection[35]. Furthermore, *H. pylori* can potentially regulate esophageal motility[55], gastric emptying, gastric accommodation of ingested food, gastric acid secretion, mucosal blood flow, hypersensitivity to chemo- and mechano-stimulants[56], food intake[6,19], digestive tract endocrine and immune functions and the composition of gut microbiota[6,18,21,22], by influencing the release of various neurotransmitters, including acetylocholine (vagal nerve, parasympathetic part), noradrenaline, adrenaline and sympathetic dopamine, as well as the neuropeptides leptin, ghrelin, calcitonin gene-related peptide (CGRP), nitric oxide, neuropeptide Y, substance P (SP), somatostatin (STS) and cholecystokinin (CCK). Moreover, *H. pylori* infection is associated with the up-regulation of toll-like

receptors and cytokine overproduction, especially tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, IL-6, and IL-8[57-59], thereby indirectly influencing the brain-gut axis. These immune-mediators may stimulate mast cells (MC) in the gastric mucosa, as well as the hypothalamus and brain stem (*via* neuroendocrine-immuno crosstalk)[6,22], thereby activating the sympathetic ANS and pituitary-suprarenal axis, resulting in increased cortisol and adrenalin secretion[6,21,22,60,61].

ROLE OF THE BRAIN-GUT AXIS IN ACUTE *H. PYLORI* INFECTION

H. pylori infection occurs *via* the oral route and, like other contagions, depends on the balance between bacteria virulence (urease, AmiE, AmiF, hydrogenase and arginase, BabA, SabA and ureaseA), host immunity and environmental factors[62]. The brain-gut axis may modulate the local immunological resistance related to gastric and gut-associated lymphoid tissue (neuroendocrine-immune crosstalk). However, these interactions are bidirectional and seem to be more complicated with regard to *H. pylori* infection. For example, nervous system disorders and the lack of MC in the gastric mucosa may predispose an individual to *H. pylori* infection, while at the same time, acute *H. pylori* infection may change both CNS and ANS activity[2,22,29,37,63,64]. Autonomic neuropathy facilitates gastric mucosal colonization and hinders *H. pylori* eradication *via* the slowing of gastric emptying, changes in gastric mucosal blood flow and immunosuppression of relative hypersympatheticotonia[2,37,60,63,64]. In an animal model, Guo *et al*[63] found that psychological stress increased *H. pylori* colonization and gastric mucosal injury. Studies by Gulcelik *et al*[65] and Gentile *et al*[37], demonstrated a higher prevalence of *H. pylori* in type 2 diabetics with cardiovascular autonomic neuropathy, but not with other common diabetic complications, such as nephropathy and retinopathy. Diabetic patients also commonly experience dyspeptic symptoms as a result of disturbances in gastric emptying, gastric wall accommodation and visceral hypersensitivity. These abnormalities, particularly efferent and vagal dysfunction, may be secondary to ANS activity[66,67]. Testoni *et al*[68] also showed a significantly greater prevalence of *H. pylori* infection in patients without evidence of gastric phase III of the migrating motor complex. Collectively, these data indicate that the coexistence of ANS dysfunction and *H. pylori* infection is a necessary condition for *H. pylori* invasion, as well as for chronic gastritis and peptic ulcer formation[6,14,15,21,22,29,35-39] (but see Chang *et al*[69]).

While it is known that acute intestinal infection during psychological or physical stress may evoke gastrointestinal symptoms and lead to increased mucosal MC infiltration[19], there is little information available concerning the effect of acute *H. pylori* infection on brain-gut axis function. The main mechanism for post-infectious IBS is infiltration and long-term maintenance of MCs in the digestive tract[6,16,21,22]. MC number and activity are increased in the gastric mucosa of patients with functional dyspepsia, independent of inflammation[70], as well as in subjects with *H. pylori*-associated gastritis[71-75]. MCs are actively involved in the pathogenesis of *H. pylori*-infected gastritis acting as important effectors of the brain-gut axis by translating stress signals into the release of a wide range of neurotransmitters and proinflammatory cytokines capable of altering gastric nerve and muscle function[6,70]. Furthermore, MCs may act *via* gastritis maintenance and reparation of injured tissue. MCs can initiate and promote edema by secreting multiple, degranulated chemotactic factors that induce the infiltration of inflammatory cells[73], as well as promote tissue turnover by stimulating the degradation of pericellular matrices and the growth of cells in their vicinity. In chronic *H. pylori* infection, these processes continue until the bacteria are eradicated. In this way, both acute and chronic *H. pylori* infection could contribute to the pathogenesis of functional dyspepsia and gastritis symptoms[9,70], especially in patients who have acquired excessive responsiveness to stress, such as a result of environmental influences during early life, genetic abnormalities, residual inflammation after gastrointestinal infections, psychophysiological abnormalities, abnormal secretion of gastric acid, diet and lifestyle[6,76]. Moreover, as with every acute infection, *H. pylori* may evoke flu-like symptoms and neuroendocrine alterations. Oral administration of *Campylobacter jejuni* or *Citrobacter rodentium* leads to the activation of vagal sensory neurons and brain regions associated with viscerosensory pathways and the central autonomic network in mice[77]. These local stomach and gut infections were associated with increased anxiety-like behavior, reminiscent of the sickness syndrome typically seen following systemic administration of bacteria or bacterial products, such as lipopolysaccharides. Furthermore, *H. pylori*-infected mice show an upregulation of SP expression, which may increase visceral mechanosensitivity in the spinal cord[56].

The pathophysiological interactions between *H. pylori* and the brain-gut axis likely involve (Figure 1): (1) axon injury or stimulation (neuroinflammation) by bacterial cytotoxins (VacA)[60,72,78], neutrophil-attractant chemokine IL-8[79], and/or neutrophil-activating protein (*H. pylori*-NAP)[75,79]; (2) axon damage or stimulation by autoimmunological reactions due to mimicry of VacA, bacterial aquaporin (AQP), *H. pylori*-NAP and human antigens[51,53,79,80]; (3) *H. pylori*-induced production of free radicals[80-82], cytotoxins and cytokines[57-61,78], which may also result in blood-brain barrier disruption; (4) changes in neurotransmitter secretion in gastric mucosa and spinal cord[56,72,75,81,83-85]; (5) neuron injury resulting from gastric mucosa atrophy and a decrease in vitamin B12 absorption[86]; and (6) changes in stomach and intestinal microbiota[6,87-89].

ROLE OF THE BRAIN-GUT AXIS IN CHRONIC *H. PYLORI* INFECTION

Reports concerning chronic *H. pylori* infection show abnormalities in neuroendocrine activity and in the digestive

Figure 1 Pathophysiology of *Helicobacter pylori* infection on the brain-gut axis. CRF: Corticotropin releasing factor; TNF-α: Tumor necrosis factor-alpha; IL: Interleukin; NAP: Neutrophil-activating protein; *H. pylori*: *Helicobacter pylori*; NAC: Neutrophil activating capacity.

tract related to *H. pylori* virulence, and disappearance following eradicative therapy. Li *et al*[83] showed greater neuronal expressions of c-fos, vasoactive intestinal peptide (VIP) and CGRP in the stomach and spinal cord of *H. pylori*-infected animals, which they proposed could form a basis for the appearance of functional dyspeptic symptoms in *H. pylori*-infected patients, as these neuropeptides are involved in the sensitization of afferent neuronal pathways[84]. Similarly, Bercík *et al*[56] showed a decrease in acetylcholine release by electric field stimulation and a higher density of SP-, CGRP-, and VIP-immunoreactive nerves in the stomach and spinal cord as well as an increase in pro-opiomelanocortin (POMC) secretion[19] in *H. pylori*-infected mice. Eradication of *H. pylori*-normalized functional and morphological abnormalities, except for the increased density of gastric SP- and CGRP-immunoreactive nerves, which may be the basis for neuromuscular changes that produce dysmotility and hyperalgesia. This observation may have many clinical consequences, as POMC is a precursor for several important biologically active substances, including N-terminal peptide of pro-opiomelanocortin (or pro-γ-MSH), γ-melanotropin, adrenocorticotropic hormone, α-melanocyte-stimulating hormone, corticotropin-like intermediate peptide, β-lipotropin, γ-lipotropin, β-melanotropin, β-endorphin and met-enkephalin.

Neuronal and non-neuronal levels of SP, VIP, CGRP and neprilysin activity were examined in freshly frozen biopsies taken from patients with chronic gastritis or ulcers in a study by Erin *et al*[85] showing that neuronal SP, mucosal VIP and neprilysin levels decreased significantly in normal appearing mucosa in patients with gastritis, while levels of mucosal SP increased in areas of gastritis and ulcer. In this study the presence of *H. pylori* was associated with further decreases in SP levels. Hydrolysis of SP by neprilysin is known to have gastroprotective effects, therefore the decreased levels of VIP, SP and neprilysin were considered by the authors as a predisposition to cellular damage. In contrast, Dömötör *et al*[90] concluded that capsaicin-sensitive afferent nerves with gastroprotective properties do not participate in the harmful effects of *H. pylori* as they found that although the expression of the capsaicin receptor, CGRP and SP were significantly higher in the mucosa of patients with chronic gastritis, there were no significant differences between *H. pylori*-positive and *H. pylori*-negative cases.

A proportion of *H. pylori* effects on the brain-gut axis

may be secondary to central and peripheral nerve demyelination and blood-brain barrier disruption[79]. The cross-mimicry between VacA and *H. pylori*-NAP is recognized as the most important immunological reaction[79], which induces autoreactive T cells and initiates or worsens gastric autoimmunity leading to atrophic gastritis and gastric cancer[91,92]. Cross-reactivity of anti-VacA antibodies with ion channels in Schwann cell plasmalemma could potentially induce demyelination, since cross-mimicry between *H. pylori* VacA and the human Na^+/K^+-ATPaseA subunit was identified by sequence homology. Cross-mimicry between *H. pylori*-NAP and/or anti-bacterial AQP antibodies and neural tissues is also possible. Whereas blood-brain barrier disruption may be secondary to the effects of *H. pylori*-induced inflammatory mediators, it can lead to increased brain vessel permeability for immunomediators, non-specific antibodies, AQP4-specific antibodies and inflammatory cells (*e.g.*, lymphocytes), which can evoke many pathological processes in the CNS, including demyelination, local edema and neuroinflammation. These processes are recognized as important for associations between *H. pylori* infection and the pathogenesis of demyelination, multiple sclerosis and neuromyelitis optica[51,52,79].

Intermediate effects of chronic *H. pylori* infection on brain-gut axis function have been clinically observed as: (1) the alteration of feeding patterns[15,19]; (2) cognitive and memory dysfunction[18,19,27,82,93], increased vulnerability to stress[15,19,27] and anxiety- and depressive-like behaviors[19]; (3) alterations in endocrine functions of the stomach, including the production of SP, VIP, CCK, STS, gastrin and ghrelin[81,94]; (4) changes in visceral ANS balance and the action of vagal visceral reflexes[95]; (5) alterations in gastrointestinal motility[21]; (6) increased visceral perception (chemo- and mechano-hypersensitivity)[67,96]; (7) changes in gastrointestinal secretion[21,45]; (8) increased intestinal permeability[23,61]; (9) intestinal microbiota[87-89], with indirect effects on the brain-gut axis[27,28,97-99]; (10) alterations in immunological reactivity, resulting in decreased prevalence of food allergies and inflammatory bowel diseases[46,100]; and (11) the overlapping of gastrointestinal disorders from upper and lower parts of the digestive tract[43]. Moreover, *H. pylori* eradication has also been shown to normalize some of these alterations[55,95,100-103].

H. PYLORI INTERACTIONS WITH THE BRAIN-GUT AXIS IN THE REGULATION OF FEEDING PATTERNS, APPETITE AND WEIGHT CONTROL

Clinical practice shows appetite improvement and increased body weight following *H. pylori* eradication[104,105]. Furthermore, corresponding changes in plasma and/or the gastric mucosal levels of hormones regulating appetite and/or energy expenditure were identified, such as ghrelin and leptin, two hormones primarily produced, stored and secreted by the gastric mucosa[106]. An animal model of *H. pylori* infection also showed abnormal feeding behavior observed as an increase in eating frequency and a decrease in the quantity of food consumed per meal[56]. These changes in feeding behavior were accompanied by elevated plasma ghrelin, postprandial CCK and higher TNF-alpha, along with reduced POMC mRNA in the arcuate nucleus of the brain. However, eradication therapy had no effect on eating behavior in this study, despite the normalization of gastric emptying and sensitivity.

A study of dyspeptic patients by Ulasoglu *et al*[55] found decreased ghrelin and increased obestatin blood levels after *H. pylori* eradication, which were greatest in overweight and male patients. However, Francois *et al*[102] reported a postprandial increase in ghrelin and leptin levels, and an increase in body mass index (BMI) in subjects 7-18 mo after successful *H. pylori* eradication treatment. Restored tissue levels of ghrelin and an improved appetite were also achieved after gastric ulcer healing and *H. pylori* eradication in studies by Roper *et al*[106], Jang *et al*[107] and Osawa *et al*[108]. Similar results were also obtained by Yang *et al*[101], who found lower serum ghrelin levels, reduced body weight and height and lower BMI and body weight gain in *H. pylori*-infected children, with restored ghrelin levels and increased growth observed one year after *H. pylori* eradication. Increased plasma and gastric mucosal ghrelin levels after *H. pylori* eradication were also shown by Deng *et al*[103] in 50 children with *H. pylori*-associated functional dyspepsia. However, a study reported by Choe *et al*[109] failed to show a relationship between *H. pylori* infection and stomach mucosal ghrelin levels, with no effect of eradication therapy. It should be noted that a greater BMI and corpus predominant gastritis are recognized as independent risk factors for eradication failure[110].

H. PYLORI INTERACTIONS WITH THE BRAIN-GUT AXIS IN BEHAVIOR, COGNITIVE FUNCTION AND MENTAL DISORDERS

The participation of the brain-gut axis in associations between bacterial flora in the bowel and some behavior patterns, and cognitive and mental disorders as well as their improvement following antibiotic, pre- and/or probiotic administration, have been reported previously, both in animals[19,24,25,93,97-99] and in humans[6,14,27,28]. It is also possible that psychiatric disorders in *H. pylori*-infected subjects result from disease overlap, with comorbidity in 40% of patients with functional dyspepsia, of which depression is the most prevalent (24%)[111].

Bacterial infection of germ-free mice evokes anxiety-like behavior, which is relieved after introducing normal gut microbiota[19,24,25,97-99]. A corresponding increase in brain-derived neurotrophic factor (BDNF) in the hippocampus and amygdala was observed that also diminished after antibiotic therapy in these mice[19]. BDNF is

involved in the neurobiology of depression[112], and is also considered a biomarker for gastric hypersensitivity and an overactive bladder[113,114]. Moreover, stress-induced memory dysfunction in mice after bacterial infection was reported by Gareau *et al*[93].

In a large, cross-sectional study of United States adults by Beydoun *et al*[115], *H. pylori*-seropositivity was associated with poor cognition based on declining verbal memory test performance. *H. pylori*, as with other urease-positive bacteria that produce ammonia, is also recognized as a cause of liver-like encephalopathy[116]. In a study by Roubaud Baudron *et al*[117] who followed-up individuals aged 65 years or older for 20 years, *H. pylori* infection was recognized as a significant risk factor for the development of dementia as a result of enhanced neurodegenerative processes, a hypothesis that has been suggested by Deretzi *et al*[80]. Moreover, a study by Muhsen *et al*[118] indicated that *H. pylori* might also negatively affect early cognitive development. In our own study, depressive and alexithymic alcoholics had less intensive *H. pylori* antral colonization than subjects with lower Beck Depression Inventory and Toronto Alexithymia Scale scores[29]. In a study by Ozdemir *et al*[119], a significant association was observed between schizophrenia and diminished risk of duodenal and gastric but not gastro-jejunal ulcers. The authors concluded that schizophrenia and attendant neurobiological mechanisms (*e.g.*, variability in dopamine pathways) may therefore modify the risk of gastric and duodenal ulcers as both central and peripheral dopamine pathways influence ulcer pathogenesis, and dopamine agonists preclude antagonists from augmenting stress - and chemically - induced gastrointestinal ulcers in preclinical models.

Probiotics reduce the adverse effects, prevent complications and improve the outcome of *H. pylori*-eradicative therapy[120]. Furthermore, *Bifidobacterium bifidum* YIT 4007 in fermented milk suppresses *H. pylori* growth[100]. However, research concerning the effect of probiotic supplementation on brain-gut axis function and mental disorders in subjects with *H. pylori* is lacking, as is data regarding the adverse effect of eradicative therapy on intestinal microbiota for a sub-form of dysbiosis in the stomach[89]. Myllyluoma *et al*[88] showed that the triple standard *H. pylori*-eradicative therapy (clarithromycin, amoxicillin and lansoprazole) significantly changed the quantities of the predominant bacterial groups both in *H. pylori*-positive and *H. pylori*-negative patients, with disturbances observed up to nine weeks after treatment completion. In their study, a combination of probiotics containing *Lactobacillus rhamnosus* GG, *L. rhamnosus* LC705, *Propionibacterium freudenreichii* spp., *Shermanii* JS and *Bifidobacterium breve* Bb99 only slightly counteracted the effects of anti-*H. pylori* treatment, seen as significantly fewer alterations in the total numbers of aerobes and lactobacilli/enterococci. However, it was found that probiotics in animal models reduced vagal-dependent activation of GABA receptors in response to physical or psychological stress[6,19]. Moreover, probiotics prevented stress-induced memory defi-

cits in mice, reduced BDNF and c-fos expression in the hippocampus, as well as attenuated corticosterone release in response to stress[27,93,97-99].

H. PYLORI AND ANS ACTIVITY

The ANS is the most important part of the brain-gut axis, containing afferent and efferent pathways regulating saliva and gastric juice secretion, mucosal blood flow, inflammatory process activity, digestive tract motility and visceral pain threshold (visceral sensitivity)[15,21,22,35,56]. Disturbances in ANS balance are observed in patients presenting with *H. pylori* infection and functional and organic digestive tract disorders[10,14,15,21,22,29,35-39]. Our study found that among patients diagnosed as a result of atypical chest pain, subjects infected with *H. pylori* had increased ANS activity, an effect that was confirmed by multifactorial analysis[35]. Moreover, our study showed negative relationships between *H. pylori* infection and esophageal sensitivity to acid, the number of acid gastroesophageal refluxes, and time spent at a gastric pH < 4, as well as positive relationships between *H. pylori* and the efficacy of esophageal peristalsis, and the amplitude and duration of esophageal contractions. We therefore concluded that gastric mucosal colonization by *H. pylori* affects ANS activity and can evoke disturbances in esophageal and gastric function. Vagal nerve predominance, as diagnosed by heart rate variability analyses, was also recognized as a risk factor for duodenal ulcer development[2,38-39,121]. Lugon *et al*[122] reported blunted sympathetic reactivity and an exacerbated vagal response to feeding in *H. pylori*-positive subjects. However, Katoh *et al*[36] have shown that *H. pylori* eradication in duodenal ulcer patients does not change nocturnal sympatheticotonia or parasympatheticotonia, which may be the cause for persistently increased gastric acid secretion, gastric mucosal vasoconstriction and ulcer recurrence[38,121], though the time course between eradication and ANS evaluation may have been too short to reveal statistically significant differences. Indeed, Stanghellini *et al*[123] suggest there is long-term recovery of *H. pylori*-induced neuroplastic changes in the ANS and highlight the importance of an incomplete resolution of gastritis and the presence of a persistent production of inflammatory mediators even after successful *H. pylori* eradication. However, Thor and Blaut[124] suggest that *H. pylori* eradication restores the parasympatheticotonic imbalance *via* a ghrelin-leptin interplay. Shahabi *et al*[125] further suggest that *H. pylori* infection of the gastric mucosa may induce a T-helper-1-like immune response and production of proinflammatory cytokines, which can inhibit local, and increase systemic, sympathetic and cholinergic tone. Such ANS changes can inhibit inflammation in the esophagus and stomach.

It is known that the brain-gut axis, including the CNS, PNS and ANS, modulates visceral reflex activity. This activity is responsible for the local regulation of digestive tract function, such as the gastric and intestinal phase of gastric or pancreatic juice secretion, esophageal, gastric

and jejunal motility and visceral sensitivity. Furthermore, visceral reflexes regulate the remote effect of gastrointestinal stimulation, including the cardio-esophageal or gastro-cardiac reflexes responsible for coronary artery spasm in response to esophageal acidification or distension. In return, coronary angioplasty can induce esophageal motility abnormalities, a decrease in the pain threshold and esophageal and gastric hyperalgesia, *via* cardio-esophageal reflex activation[67,95]. As these effects were only observed in 56% of subjects with non-cardiac chest pain[95], reciprocal modulation by the brain-gut axis may have had further influence along with individual reactions to stress[6,21,22]. Thus, more research is needed concerning the effect of *H. pylori* infection on visceral reflexes.

H. PYLORI AND VISCERAL SENSITIVITY

Visceral hypersensitivity is a symptom of functional digestive tract disorders that may be modulated by *H. pylori* infection and the brain-gut axis[76]. The brain-gut axis plays an important role in the tonic or phasic up- or downregulation of afferent and efferent nerve sensitivities[18,21,22]. Visceral afferent pathways (enteric, spinal and vagal) transmit signals from the stomach to the CNS. As mentioned above, these afferents may also modulate emotion, pain, satiety and immunity in response to emotional influences or environmental demands. Visceral hypersensitivity may also be affected by hypersympatheticotonia. However, both hypervagotonia and hypersympatheticotonia may change efferent nerve activity due to modulation of vagal visceral reflex activity and the patient's digestive tract response to visceral or environmental stimuli[67].

H. pylori infection may additionally affect brain-gut axis function and visceral sensitivity by neurotransmitter and hormone release and activation of inflammatory processes[61], as well as induce digestive tract dysmotility and trigger neuroplastic changes in the afferent neural pathways leading to visceral hyperalgesia[123]. A reduction in central antinociceptive control systems, visceral pain modulators both in digestive tract disorders and extra-gastric syndromes, may also play a pathophysiological role in *H. pylori* infection.

Bercík *et al*[56] found that an increase in visceral perception (mechanosensitivity) in *H. pylori*-infected mice was related to an increase in vagal SP expression. Similarly, Mönnikes *et al*[126] showed that discomfort and pain thresholds on gastric distension were lower in patients with functional dyspepsia that were *H. pylori*-positive. These patients also showed higher antral mucosal levels of CGRP and SP, which negatively correlated with the levels of discomfort and pain thresholds, demonstrating the role of the brain-gut axis in hypersensitivity and SP and CGRP involvement in the sensitization of afferent neuronal pathways, which result from chronic inflammation[84,126]. Similar inflammation-related changes in sensory-motor function have been observed in subjects with intestinal mucosal inflammation[9,11,123]. The role of *H.*

pylori infection in the symptoms of functional dyspepsia was also confirmed by a Cochrane review, which reported that eradication of *H. pylori* had a small but statistically significant long-term effect on symptom relief when compared with a placebo, lasting at least 12 mo after one week of eradication therapy, expressed more in patients from Asian rather than Western countries[92,127]. However, Mearin *et al*[128] found that *H. pylori*-infected patients with functional dyspepsia presented no distinctive symptoms compared to their *H. pylori*-negative counterparts. Furthermore, additional placebo-controlled trials and a meta-analysis did not show improvement in dyspeptic symptoms with *H. pylori* eradication[129-131]. Discrepancies regarding symptomatic response to *H. pylori* eradication may relate to commonly occurring comorbid psychiatric disorders, which can affect treatment outcome[111]. *H. pylori* infection is also considered a cause of visceral hypersensitivity in patients with IBS, as individuals reporting typical abdominal discomfort after rectal barostat testing were more frequently *H. pylori* positive[42,43].

Disturbances in ANS activity, particularly hyperparasympatheticotonia, should also be recognized as a factor responsible for the clinical manifestation of lowered pain thresholds. *H. pylori* infection may increase sympathetic ANS activity *via* induction of gastritis and overproduction of systemic inflammatory mediators through a pathogen-burden mechanism[61]. Increased ANS activity is related to symptom thresholds in patients with peptic ulcers[38-39,121], in acid-sensitive and insensitive patients with non-cardiac chest pain[67], in patients with non-specific disorders of esophageal motility[132], as well as in individuals with functional dyspepsia[9,21,42,66,76,94,126,133] and IBS[134]. Such a pathway is also considered as one of the causes of pain in *H. pylori*-infected patients with fibromyalgia[96].

H. PYLORI AND DIGESTIVE MOTILITY

Digestive tract motor disorders are a source of functional symptoms originating from the upper and lower parts of the digestive tract[76]. Typical gastric motility abnormalities involve impaired fundic accommodation and reduced compliance to meals, impaired initial distribution of a meal, antral hypomotility, altered myoelectric activity and gastric emptying and disturbed gastro- and duodeno-jejunal motor coordination[133]. Delayed gastric emptying has been described in about 30%-80% of patients with functional dyspepsia as a result of antral or fundal hypomotility, uncoordinated antro-pyloro-duodenal activity or inhibitory feedback of the intestine[135]. Symptoms of motility disorders may be evoked through the activation of chemo- (delayed clearance) and mechano-receptors (digestive tract tube contraction or extension due to hypertensive spasm or dilatation proximal to contraction), *via* activation of viscerosomatic reflexes, and somatic receptors localized in the distended abdominal wall in the course of bloating, especially in individuals with hypersensitivity to stress. Furthermore, symptoms relating to reflux of gastric content into the esophagus, or other causes of

delayed gastric emptying and/or its accommodation impairment, may appear in patients with gastroparesis[136].

The effect of *H. pylori* infection on digestive tract motility may result from its direct local action, or an intermediate effect *via* the above-described ANS and endocrine effects (*i.e.*, due to alteration in gastrin, STS, CCK and plasma and mucosal ghrelin levels)[137-140]. However, there are no recent studies on the effect of *H. pylori* infection and its eradication on esophageal and gastric motility. Chiloiro *et al*[140] showed higher gastrin and lower CCK plasma levels in *H. pylori*-infected patients with functional dyspepsia, but did not find a difference in gastric emptying. Similarly, Schenk *et al*[137] showed that severe hypergastrinemia during omeprazole maintenance therapy for gastroesophageal reflux was associated with the duration of therapy and *H. pylori* infection, but not with abnormalities of gastric emptying or vagal nerve integrity. Currently, there are no reports concerning the effect of *H. pylori*-induced hypergastrinemia secondary to hypochloremia in the course of *H. pylori* infection-related gastric corpus mucosa atrophy. However, an *in vitro* study showed that eradication of *H. pylori* did not affect muscle contractility and acetylcholine release but augmented antral relaxation after nerve electrical field stimulation[56].

A study by our group found positive relationships between *H. pylori* infection and the efficacy of esophageal peristalsis and the amplitude and duration of esophageal contractions in patients with atypical chest pain[35]. However, Tsai *et al*[141] and Zerbib *et al*[142] did not find any differences in the patterns of esophageal motility and transient lower esophageal sphincter relaxations between *H. pylori*-positive and *H. pylori*-negative subjects. Similarly, Tanaka *et al*[143] did not observe changes in gastric and esophageal function after *H. pylori* eradication, besides an increase in gastric acidity at night, suggesting that *H. pylori* does not produce esophageal-motility-related chest pain, although it induced a more active inflammatory process in esophageal mucosa[142].

The presence of *H. pylori* infection also did not significantly affect gastric emptying rates for solids and liquids, discomfort sensitivity thresholds, or meal-induced gastric relaxation in dyspeptic patients[144]. *H. pylori*-positive and -negative patients in a study by Mearin *et al*[128] also suffered from similar severity and frequency of dyspeptic symptoms and global symptom scores, and presented no differences in gastric compliance. However, postprandial antral motility in *H. pylori*-positive patients was significantly decreased, though without an increase in their perception of gastric distension. A report by Thumshirn *et al*[145] showed that impaired gastric accommodation is frequent in non-ulcer dyspepsia, but unrelated to *H. pylori* infection and vagal efferent dysfunction. Additionally, a placebo-controlled double-blind study showed that *H. pylori* eradication in patients with functional dyspepsia had no impact on gastric emptying as estimated using a standardized scintigraphic double-tracer[146]. Furthermore, a decreased prevalence of normal electrogastrography (EGG) patterns was found in both *H. pylori*-positive and

-negative patients with functional dyspepsia compared to healthy controls, though only subjects with delayed gastric emptying achieved symptom improvement and normalization of the EGG pattern after *H. pylori* eradication[135]. In contrast, a study by Simrén *et al*[20] indicated that *H. pylori* infection was independently associated with the presence of unsuppressed phasic fundic contractility after a meal, which induced a transient increase in gastric wall tension that was observed in 15% of subjects. Lin *et al*[147] found abnormal gastric myoelectrical activity in approximately 40% of *H. pylori*-infected patients with functional dyspepsia, which was normalized in some following *H. pylori* eradication, with similar observations reported by Thor *et al*[148]. In a double-blind study performed in patients with duodenal ulcers, Konturek *et al*[139] showed that *H. pylori* infection was accompanied by enhanced gastric emptying and reduced luminal release of STS, although a CCK antagonist had no effect in *H. pylori*-infected subjects. The authors therefore concluded that, since gastric motor function and STS secretion were normalized after *H. pylori* eradication, CCK and STS contribute to the normalization of gastric emptying following *H. pylori* eradication in patients with duodenal ulcer.

Current data demonstrate contrary outcomes of the effect of *H. pylori*-infection on digestive tract motor function, and further studies are therefore needed to address these discrepancies as well as the involvement of the brain-gut axis. Indeed, this has been suggested by Manes *et al*[149] who highlighted the low quality of the studies performed, methodological problems relating to the small numbers of patients, differences in methodological approaches and the well-known difficulties in studying both gastrointestinal motility and functional dyspepsia.

H. PYLORI AND GASTROINTESTINAL SECRETION

The known phrase, "no acid - no ulcer" emphasizes the important role of gastric acid secretion in the pathogenesis of upper digestive tract symptoms and injuries. As *H. pylori* infection is recognized as the main ulcerogenic factor, it is an important pathomechanism of direct and immediate harmful *H. pylori* action *via* the brain-gut axis. The effect of *H. pylori* infection on gastric acid secretion depends on the location of the gastritis. In localization of the antral inflammatory process, acid hypersecretion was observed, leading to stomach mucosal atrophy and hypochlorhydria in patients with corporal gastritis or pangastritis[141]. After *H. pylori* eradication, intragastric pH in the postprandial period was significantly lower, whereas baseline pH remained unchanged[150]. These changes were expressed particularly in patients with the proinflammatory *IL-1B* genotype, which is associated with an increased risk of gastric mucosa atrophy, lower gastric acidity and gastric carcinoma[151].

Chronic gastritis also affects a variety of endocrine functions of the stomach, including the production of STS, gastrin and ghrelin[94]. As gastric parietal cells are

regulated by hormones and neurotransmitters, such as gastrin, histamine and acetylocholine, analysis of the effect of *H. pylori*-infection on the brain-gut axis is reasonable. *H. pylori* infection leads to a decrease in gastric acid secretion due to mucosal atrophy and vagal nerve dysfunction[81], which may result in alteration of both gastric motility and secretion, as well as food intake.

Abnormal vagal nerve activity should be considered as a potential mediator of *H. pylori*-induced changes in secretion of gastric acid, gastrin and ghrelin. However, there are no recent studies investigating the effect of *H. pylori* infection and eradication on gastric acidity. Lucini *et al*[39] examined the association between ANS activity and gastric acid secretion and found that sham-fed patients with duodenal ulcers had greater vagal and lower sympathetic nerve activities using heart rate variability (HRV) analyses. In these patients, the sham feeding to basal acid output ratio value correlated with markers of ANS activity. A study by Nada *et al*[121] reported high sympatho-vagal tone at night in patients with peptic ulcers, which can result in gastric artery spasms and excess secretion of gastric acid. In the same study, HRV markers of vagal nerve activity and gastric juice secretion increased in adult mongrel dogs following an intravenous injection of insulin.

H. pylori-positive patients with duodenal ulcers showed increased plasma gastrin concentrations in a study by Iijima *et al*[152], while *H. pylori*-positive patients with gastric ulcers showed lower concentrations compared to *H. pylori*-negative counterparts. In both groups, the gastrin plasma levels changed after *H. pylori* eradication, decreasing in individuals with duodenal ulcers, and increasing in those with gastric ulcers. Ghrelin is also secreted by gastric mucosa cells, and not only regulates food intake, but also exhibits an effect on gastroprotection and increases esophageal and gastric motility and gastric acid secretion[6,14,124,148,153].

CONCLUSION

H. pylori infection, the main pathogenic factor of upper digestive tract organic diseases, displays not only local cytotoxic and proinflammatory effects, but may also exert systemic action *via* modulation of the brain-gut axis. These relationships are bidirectional and influence the contagion process and the host neuro-endocrine immunological reaction, including alterations in cognitive functions, modification of symptom sensitivity thresholds and digestive tract secretion and motility. The effect on the brain-gut axis by this microorganism may arise from a direct neurotoxic effect, activation of inflammatory processes in nerves and microelement deficiency. However, many of the investigations concerning the interplay between *H. pylori* and the effects on brain-gut axis activation are dated. Therefore, further studies are necessary to evaluate the clinical importance of these host-bacteria interactions. Results from such studies will improve our understanding of *H. pylori* infection pathophysiology and suggest new therapeutic approaches.

REFERENCES

1   **Melmed RN**, Gelpin Y. Duodenal ulcer: the helicobacterization of a psychosomatic disease? *Isr J Med Sci* 1996; **32**: 211-216 [PMID: 8606137]

2   **Moriya M**, Uehara A, Okumura T, Miyamoto M, Kohgo Y. Stress-induced hemorrhagic gastric ulcer after successful Helicobacter pylori eradication: two case reports. *J Med Case Rep* 2011; **5**: 252 [PMID: 21714884 DOI: 10.1186/1752-1947-5-252]

3   **Malfertheiner P**, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012; **61**: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]

4   **Stenström B**, Mendis A, Marshall B. Helicobacter pylori -the latest in diagnosis and treatment. *Aust Fam Physician* 2008; **37**: 608-612 [PMID: 18704207]

5   **Aoyama N**, Shinoda Y, Matsushima Y, Shirasaka D, Kinoshita Y, Kasuga M, Chiba T. Helicobacter pylori-negative peptic ulcer in Japan: which contributes most to peptic ulcer development, Helicobacter pylori, NSAIDS or stress? *J Gastroenterol* 2000; **35** Suppl 12: 33-37 [PMID: 10779215]

6   **Konturek PC**, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. *J Physiol Pharmacol* 2011; **62**: 591-599 [PMID: 22314561]

7   **Svoboda P**, Kantorova I, Scheer P, Doubek J, Ochmann J, Rehorkova D, Bosakova H. Helicobacter pylori is not a risk factor for stress ulcer bleeding in polytraumatized patients. *Hepatogastroenterology* 2004; **51**: 476-480 [PMID: 15086186]

8   **van der Voort PH**, van der Hulst RW, Zandstra DF, Geraedts AA, van der Ende A, Tytgat GN. Prevalence of Helicobacter pylori infection in stress-induced gastric mucosal injury. *Intensive Care Med* 2001; **27**: 68-73 [PMID: 11280676]

9   **Keohane J**, Quigley EM. Functional dyspepsia: the role of visceral hypersensitivity in its pathogenesis. *World J Gastroenterol* 2006; **12**: 2672-2676 [PMID: 16718751]

10 **Charpignon C**, Lesgourgues B, Pariente A, Nahon S, Pelaquier A, Gatineau-Saillant G, Roucayrol AM, Courillon-Mallet A. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. *Aliment Pharmacol Ther* 2013; **38**: 946-954 [PMID: 23981105 DOI: 10.1111/apt.12465]

11 **Jones MP**. The role of psychosocial factors in peptic ulcer disease: beyond Helicobacter pylori and NSAIDs. *J Psychosom Res* 2006; **60**: 407-412 [PMID: 16581366]

12 **Chen TS**, Chang FY. Clinical characteristics of Helicobacter pylori-negative duodenal ulcer disease. *Hepatogastroenterology* 2008; **55**: 1615-1618 [PMID: 19102353]

13 **Goodwin RD**, Talley NJ, Hotopf M, Cowles RA, Galea S, Jacobi F. A link between physician-diagnosed ulcer and anxiety disorders among adults. *Ann Epidemiol* 2013; **23**: 189-192 [PMID: 23453387 DOI: 10.1016/j.annepidem.2013.01.003]

14 **Caso JR**, Leza JC, Menchén L. The effects of physical and psychological stress on the gastro-intestinal tract: lessons from animal models. *Curr Mol Med* 2008; **8**: 299-312 [PMID: 18537637]

15 **Collins SM**, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. *Dig Liver Dis* 2009; **41**: 850-853 [PMID: 19740713 DOI: 10.1016/j.dld.2009.07.023]

16 **Mach T**. The brain-gut axis in irritable bowel syndrome -clinical aspects. *Med Sci Monit* 2004; **10**: RA125-RA131 [PMID: 15173682]

17 **Luther J**, Dave M, Higgins PD, Kao JY. Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature.

Inflamm Bowel Dis 2010; **16**: 1077-1084 [PMID: 19760778 DOI: 10.1002/ibd.21116]

18   **Mayer EA**, Tillisch K, Bradesi S. Review article: modulation of the brain-gut axis as a therapeutic approach in gastro-intestinal disease. *Aliment Pharmacol Ther* 2006; **24**: 919-933 [PMID: 16948804]

19   **Bercik P**, Verdú EF, Foster JA, Lu J, Scharringa A, Kean I, Wang L, Blennerhassett P, Collins SM. Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. *Am J Physiol Regul Integr Comp Physiol* 2009; **296**: R587-R594 [PMID: 19129375 DOI: 10.1152/ajpregu.90752.2008]

20   **Simrén M**, Vos R, Janssens J, Tack J. Unsuppressed post-prandial phasic contractility in the proximal stomach in functional dyspepsia: relevance to symptoms. *Am J Gastro-enterol* 2003; **98**: 2169-2175 [PMID: 14572563]

21   **Wood JD**. Neuropathophysiology of functional gastroin-testinal disorders. *World J Gastroenterol* 2007; **13**: 1313-1332 [PMID: 17457962]

22   **Ziemssen T**, Kern S. Psychoneuroimmunology--cross-talk be-tween the immune and nervous systems. *J Neurol* 2007; **254** Sup-pl 2: II8-II11 [PMID: 17503136 DOI: 10.1007/s00415-007-2003-8]

23   **Fukuda Y**, Bamba H, Okui M, Tamura K, Tanida N, Satomi M, Shimoyama T, Nishigami T. Helicobacter pylori infec-tion increases mucosal permeability of the stomach and intestine. *Digestion* 2001; **63** Suppl 1: 93-96 [PMID: 11173917]

24   **Neufeld KA**, Kang N, Bienenstock J, Foster JA. Effects of in-testinal microbiota on anxiety-like behavior. *Commun Integr Biol* 2011; **4**: 492-494 [PMID: 21966581]

25   **Neufeld KM**, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. *Neurogastroenterol Motil* 2011; **23**: 255-64, e119 [PMID: 21054680 DOI: 10.1111/j.1365-2982.2010.01620.x]

26   **Rhee SH**, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. *Nat Rev Gastroenterol Hepatol* 2009; **6**: 306-314 [PMID: 19404271 DOI: 10.1038/nrgastro.2009.35]

27   **Cryan JF**, Dinan TG. Mind-altering microorganisms: the im-pact of the gut microbiota on brain and behaviour. *Nat Rev Neurosci* 2012; **13**: 701-712 [PMID: 22968153 DOI: 10.1038/nrn3346]

28   **Neary NM**, Small CJ, Bloom SR. Gut and mind. *Gut* 2003; **52**: 918-921 [PMID: 12801943]

29   **Swiatkowski M**, Budzyński J, Kłopocka M, Ziółkowski M, Bujak R, Sinkiewicz W. Parameters of the functional and morphological status of the upper digestive tract in alcohol-dependent male patients with depression and alexithymia in the context of autonomic nervous system activity and ni-tric oxide plasma level. *Med Sci Monit* 2004; **10**: CR68-CR74 [PMID: 14737046]

30   **Bajaj JS**, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM. Colonic mucosal microbiome differs from stool micro-biome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. *Am J Physiol Gastrointest Liver Physiol* 2012; **303**: G675-G685 [PMID: 22821944 DOI: 10.1152/ajpgi.00152.2012]

31   **Ledochowski M**, Widner B, Bair H, Probst T, Fuchs D. Fruc-tose- and sorbitol-reduced diet improves mood and gas-trointestinal disturbances in fructose malabsorbers. *Scand J Gastroenterol* 2000; **35**: 1048-1052 [PMID: 11099057]

32   **Sandler RH**, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Väisänen ML, Nelson MN, Wexler HM. Short-term benefit from oral vancomycin treatment of regressive-onset autism. *J Child Neurol* 2000; **15**: 429-435 [PMID: 10921511]

33   **Parracho HM**, Bingham MO, Gibson GR, McCartney AL. Differences between the gut microflora of children with au-tistic spectrum disorders and that of healthy children. *J Med Microbiol* 2005; **54**: 987-991 [PMID: 16157555]

34   **Finegold SM**, Downes J, Summanen PH. Microbiology of regressive autism. *Anaerobe* 2012; **18**: 260-262 [PMID: 22202440 DOI: 10.1016/j.anaerobe.2011.12.018]

35   **Budzyński J**, Kłopocka M, Bujak R, Swiatkowski M, Pulkowski G, Sinkiewicz W. Autonomic nervous function in Helicobacter pylori-infected patients with atypical chest pain studied by analysis of heart rate variability. *Eur J Gas-troenterol Hepatol* 2004; **16**: 451-457 [PMID: 15097036]

36   **Katoh K**, Nomura M, Nakaya Y, Iga A, Nada T, Hiasa A, Ochi Y, Kawaguchi R, Uemura N, Honda H, Shimizu I, Ito S. Autonomic nervous activity before and after eradication of Helicobacter pylori in patients with chronic duodenal ulcer. *Aliment Pharmacol Ther* 2002; **16** Suppl 2: 180-186 [PMID: 11966539]

37   **Gentile S**, Turco S, Oliviero B, Torella R. The role of auto-nomic neuropathy as a risk factor of Helicobacter pylori infection in dyspeptic patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 1998; **42**: 41-48 [PMID: 9884032]

38   **Nomura M**, Yukinaka M, Miyajima H, Nada T, Kondo Y, Okahisa T, Shibata H, Okamura S, Honda H, Shimizu I, Saito K, Oki T, Nakaya Y, Ito S. Is autonomic dysfunction a necessary condition for chronic peptic ulcer formation? *Aliment Pharmacol Ther* 2000; **14** Suppl 1: 82-86 [PMID: 10807408]

39   **Lucini D**, Cerchiello M, Basilisco G, Cainelli M, Bianchi PA, Fiorelli G, Malliani A, Pagani M. Autonomic control of heart period in duodenal ulcer patients insights from spectral analysis of heart rate variability. *Auton Neurosci* 2000; **84**: 122-129 [PMID: 11111844]

40   **Sharma A**, Lelic D, Brock C, Paine P, Aziz Q. New technolo-gies to investigate the brain-gut axis. *World J Gastroenterol* 2009; **15**: 182-191 [PMID: 19132768]

41   **Longstreth GF**, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. *Gastro-enterology* 2006; **130**: 1480-1491 [PMID: 16678561]

42   **Su YC**, Wang WM, Wang SY, Lu SN, Chen LT, Wu DC, Chen CY, Jan CM, Horowitz M. The association between Helicobacter pylori infection and functional dyspepsia in patients with irritable bowel syndrome. *Am J Gastroenterol* 2000; **95**: 1900-1905 [PMID: 10950033]

43   **Gerards C**, Leodolter A, Glasbrenner B, Malfertheiner P. H. pylori infection and visceral hypersensitivity in patients with irritable bowel syndrome. *Dig Dis* 2001; **19**: 170-173 [PMID: 11549828]

44   **Breckan RK**, Asfeldt AM, Straume B, Florholmen J, Pauls-sen EJ. Prevalence, comorbidity, and risk factors for func-tional bowel symptoms: a population-based survey in Northern Norway. *Scand J Gastroenterol* 2012; **47**: 1274-1282 [PMID: 23061445 DOI: 10.3109/00365521.2012.688215]

45   **Domínguez-Muñoz JE**, Malfertheiner P. Effect of Helico-bacter pylori infection on gastrointestinal motility, pancreat-ic secretion and hormone release in asymptomatic humans. *Scand J Gastroenterol* 2001; **36**: 1141-1147 [PMID: 11686212]

46   **Xiang Z**, Chen YP, Ye YF, Ma KF, Chen SH, Zheng L, Yang YD, Jin X. Helicobacter pylori and Crohn's disease: a retro-spective single-center study from China. *World J Gastroen-terol* 2013; **19**: 4576-4581 [PMID: 23901235 DOI: 10.3748/wjg.v19.i28.4576]

47   **Grundy D**, Al-Chaer ED, Aziz Q, Collins SM, Ke M, Ta-ché Y, Wood JD. Fundamentals of neurogastroenterology: basic science. *Gastroenterology* 2006; **130**: 1391-1411 [PMID: 16678554]

48   **Marques AH**, Silverman MN, Sternberg EM. Evaluation of stress systems by applying noninvasive methodolo-gies: measurements of neuroimmune biomarkers in the sweat, heart rate variability and salivary cortisol. *Neuro-immunomodulation* 2010; **17**: 205-8 [PMID: 20134204 DOI: 10.1159/000258725]

49   **Budzyński J**, Pulkowski G, Suppan K, Fabisiak J, Majer M, Kłopocka M, Galus-Pulkowska B, Wasielewski M. Improve-

ment in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey. *Health Qual Life Outcomes* 2011; **9**: 77 [PMID: 21939510 DOI: 10.1186/1477-7525-9-77]

50 **Wilhelmsen I**. Quality of life and Helicobacter pylori eradication. *Scand J Gastroenterol Suppl* 1996; **221**: 18-20 [PMID: 9110391]

51 **Kountouras J**, Deretzi G, Zavos C, Tsiptsios D, Gavalas E, Vardaka E, Polyzos SA, Klonizakis P, Kyriakou P. Helicobacter pylori infection may trigger Guillain-Barré syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis. *J Neurol Sci* 2011; **305**: 167-18; author reply 169 [PMID: 21440259 DOI: 10.1016/j.jns.2011.03.015]

52 **Kountouras J**, Zavos C, Deretzi G, Polyzos SA, Katsinelos P, Anastasiadou K, Stergiopoulos C, Pilpilidis I, Klonizakis P, Boura P, Tzilves D. Helicobacter pylori might be a potential therapeutic target in epilepsy. *Med Hypotheses* 2011; **76**: 763 [PMID: 21356577 DOI: 10.1016/j.mehy.2011.02.004]

53 **Deretzi G**, Kountouras J, Grigoriadis N, Zavos C, Chatzigeorgiou S, Koutlas E, Tsiptsios I. From the "little brain" gastrointestinal infection to the "big brain" neuroinflammation: a proposed fast axonal transport pathway involved in multiple sclerosis. *Med Hypotheses* 2009; **73**: 781-787 [PMID: 19467574 DOI: 10.1016/j.mehy.2009.04.021]

54 **Eom KS**, Park MR, Choi KH, Kim TY. Gastric mucosa-associated lymphoid tissue lymphoma followed by primary central nervous system lymphoma. *J Korean Neurosurg Soc* 2012; **51**: 377-379 [PMID: 22949970]

55 **Ulasoglu C**, Isbilen B, Doganay L, Ozen F, Kiziltas S, Tuncer I. Effect of Helicobacter pylori eradication on serum ghrelin and obestatin levels. *World J Gastroenterol* 2013; **19**: 2388-2394 [PMID: 23613634 DOI: 10.3748/wjg.v19.i15.2388]

56 **Bercík P**, De Giorgio R, Blennerhassett P, Verdú EF, Barbara G, Collins SM. Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection. *Gastroenterology* 2002; **123**: 1205-1215 [PMID: 12360482]

57 **Lagunes-Servin H**, Torres J, Maldonado-Bernal C, Pérez-Rodríguez M, Huerta-Yépez S, Madrazo de la Garza A, Muñoz-Pérez L, Flores-Luna L, Ramón-García G, Camorlinga-Ponce M. Toll-like receptors and cytokines are upregulated during Helicobacter pylori infection in children. *Helicobacter* 2013; **18**: 423-432 [PMID: 23869400 DOI: 10.1111/hel.12067]

58 **Rahimi HR**, Rasouli M, Jamshidzadeh A, Farshad S, Firoozi MS, Taghavi AR, Kiany S. New immunological investigations on Helicobacter pylori-induced gastric ulcer in patients. *Microbiol Immunol* 2013; **57**: 455-462 [PMID: 23773024]

59 **Romero-Adrián TB**, Leal-Montiel J, Monsalve-Castillo F, Mengual-Moreno E, McGregor EG, Perini L, Antúnez A. Helicobacter pylori: bacterial factors and the role of cytokines in the immune response. *Curr Microbiol* 2010; **60**: 143-155 [PMID: 19847485]

60 **Vizi ES**, Elenkov IJ. Nonsynaptic noradrenaline release in neuro-immune responses. *Acta Biol Hung* 2002; **53**: 229-244 [PMID: 12064774]

61 **Peuhkuri K**, Vapaatalo H, Korpela R. Even low-grade inflammation impacts on small intestinal function. *World J Gastroenterol* 2010; **16**: 1057-1062 [PMID: 20205274]

62 **Molnar B**, Galamb O, Sipos F, Leiszter K, Tulassay Z. Molecular pathogenesis of Helicobacter pylori infection: the role of bacterial virulence factors. *Dig Dis* 2010; **28**: 604-608 [PMID: 21088410 DOI: 10.1159/000320060]

63 **Guo G**, Jia KR, Shi Y, Liu XF, Liu KY, Qi W, Guo Y, Zhang WJ, Wang T, Xiao B, Zou QM. Psychological stress enhances the colonization of the stomach by Helicobacter pylori in the BALB/c mouse. *Stress* 2009; **12**: 478-485 [PMID: 20102319 DOI: 10.3109/10253890802642188]

64 **Ding H**, Nedrud JG, Wershil B, Redline RW, Blanchard TG, Czinn SJ. Partial protection against Helicobacter pylori in the absence of mast cells in mice. *Infect Immun* 2009; **77**: 5543-5550 [PMID: 19822650 DOI: 10.1128/IAI.00532-09]

65 **Gulcelik NE**, Kaya E, Demirbas B, Culha C, Koc G, Ozkaya M, Cakal E, Serter R, Aral Y. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. *J Endocrinol Invest* 2005; **28**: 214-217 [PMID: 15952404]

66 **Tack J**, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. *Gastroenterology* 2001; **121**: 526-535 [PMID: 11522735]

67 **Tougas G**, Spaziani R, Hollerbach S, Djuric V, Pang C, Upton AR, Fallen EL, Kamath MV. Cardiac autonomic function and oesophageal acid sensitivity in patients with non-cardiac chest pain. *Gut* 2001; **49**: 706-712 [PMID: 11600476]

68 **Testoni PA**, Bagnolo F, Bologna P, Colombo E, Bonassi U, Lella F, Buizza M. Higher prevalence of Helicobacter pylori infection in dyspeptic patients who do not have gastric phase III of the migrating motor complex. *Scand J Gastroenterol* 1996; **31**: 1063-1068 [PMID: 8938898]

69 **Chang CS**, Chen GH, Kao CH, Wang SJ. Delayed gastric emptying does not predispose to Helicobacter pylori infection in non-ulcer dyspepsia patients. *Nucl Med Commun* 1995; **16**: 1063-1067 [PMID: 8719989]

70 **Hall W**, Buckley M, Crotty P, O'Morain CA. Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. *Clin Gastroenterol Hepatol* 2003; **1**: 363-369 [PMID: 15017654]

71 **Sipos G**, Altdorfer K, Pongor E, Chen LP, Fehér E. Neuro-immune link in the mucosa of chronic gastritis with Helicobacter pylori infection. *Dig Dis Sci* 2006; **51**: 1810-1817 [PMID: 16983504]

72 **Supajatura V**, Ushio H, Wada A, Yahiro K, Okumura K, Ogawa H, Hirayama T, Ra C. Cutting edge: VacA, a vacuolating cytotoxin of Helicobacter pylori, directly activates mast cells for migration and production of proinflammatory cytokines. *J Immunol* 2002; **168**: 2603-2607 [PMID: 11884423]

73 **Nakajima S**, Bamba N, Hattori T. Histological aspects and role of mast cells in Helicobacter pylori-infected gastritis. *Aliment Pharmacol Ther* 2004; **20** Suppl 1: 165-170 [PMID: 15298623]

74 **Otaka M**, Watanabe S. Role of mucosal mast cells in Helicobacter pylori infection. *J Gastroenterol* 2002; **37**: 70-72 [PMID: 11824805]

75 **Montemurro P**, Nishioka H, Dundon WG, de Bernard M, Del Giudice G, Rappuoli R, Montecucco C. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a potent stimulant of mast cells. *Eur J Immunol* 2002; **32**: 671-676 [PMID: 11857341]

76 **Miwa H**. Why dyspepsia can occur without organic disease: pathogenesis and management of functional dyspepsia. *J Gastroenterol* 2012; **47**: 862-871 [PMID: 22766746 DOI: 10.1007/s00535-012-0625-9]

77 **Gaykema RP**, Goehler LE, Lyte M. Brain response to cecal infection with Campylobacter jejuni: analysis with Fos immunohistochemistry. *Brain Behav Immun* 2004; **18**: 238-245 [PMID: 15050651]

78 **Rossetto O**, de Bernard M, Pellizzari R, Vitale G, Caccin P, Schiavo G, Montecucco C. Bacterial toxins with intracellular protease activity. *Clin Chim Acta* 2000; **291**: 189-199 [PMID: 10675723]

79 **Kountouras J**, Zavos C, Deretzi G, Gavalas E, Chatzopoulos D, Katsinelos P, Tsiaousi E, Gagalis S, Polyzos SA, Venizelos I. Potential implications of Helicobacter pylori-related neutrophil-activating protein. *World J Gastroenterol* 2012; **18**: 489-490 [PMID: 22346256 DOI: 10.3748/wjg.v18.i5.489]

80 **Deretzi G**, Kountouras J, Polyzos SA, Zavos C, Giartza-Taxidou E, Gavalas E, Tsiptsios I. Gastrointestinal immune system and brain dialogue implicated in neuroinflammatory and neurodegenerative diseases. *Curr Mol Med* 2011; **11**: 696-707 [PMID: 21902649]

81 **Suzuki H**, Matsuzaki J, Hibi T. Ghrelin and oxidative stress in gastrointestinal tract. *J Clin Biochem Nutr* 2011; **48**: 122-125 [PMID: 21373264 DOI: 10.3164/jcbn.10-16GFR]

82 **Suzuki H**, Miura S, Suzuki M, Terada S, Nakamura M, Tsuchiya M. Gastric mucosal injury: microcirculation and Helicobacter pylori. *Keio J Med* 1994; **43**: 1-8 [PMID: 8189675]

83 **Li XB**, Chen HM, Lu H, Zheng Q, Chen XY, Peng YS, Ge ZZ, Liu WZ. Role of Helicobacter pylori infection on neuronal expression in the stomach and spinal cord of a murine model. *J Dig Dis* 2009; **10**: 286-292 [PMID: 19906107 DOI: 10.1111/j.1751-2980.2009.00397.x]

84 **Xu X**, Li Z, Zou D, Yang M, Liu Z, Wang X. High expression of calcitonin gene-related peptide and substance P in esophageal mucosa of patients with non-erosive reflux disease. *Dig Dis Sci* 2013; **58**: 53-60 [PMID: 22961239 DOI: 10.1007/s10620-012-2308-z]

85 **Erin N**, Türker S, Elpek O, Yıldırım B. Differential changes in Substance P, VIP as well as neprilysin levels in patients with gastritis or ulcer. *Peptides* 2012; **35**: 218-224 [PMID: 22484287 DOI: 10.1016/j.peptides.2012.03.018]

86 **Yağci M**, Yamaç K, Acar K, Cingi E, Kitapçi M, Haznedar R. Gastric emptying in patients with vitamin B(12) deficiency. *Eur J Nucl Med Mol Imaging* 2002; **29**: 1125-1127 [PMID: 12192555]

87 **Aebischer T**, Fischer A, Walduck A, Schlötelburg C, Lindig M, Schreiber S, Meyer TF, Bereswill S, Göbel UB. Vaccination prevents Helicobacter pylori-induced alterations of the gastric flora in mice. *FEMS Immunol Med Microbiol* 2006; **46**: 221-229 [PMID: 16487303]

88 **Myllyluoma E**, Ahlroos T, Veijola L, Rautelin H, Tynkkynen S, Korpela R. Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. *Int J Antimicrob Agents* 2007; **29**: 66-72 [PMID: 17141481]

89 **Engstrand L**, Lindberg M. Helicobacter pylori and the gastric microbiota. *Best Pract Res Clin Gastroenterol* 2013; **27**: 39-45 [PMID: 23768551 DOI: 10.1016/j.bpg.2013.03.016]

90 **Dömötör A**, Kereskay L, Szekeres G, Hunyady B, Szolcsányi J, Mózsik G. Participation of capsaicin-sensitive afferent nerves in the gastric mucosa of patients with Helicobacter pylori-positive or-negative chronic gastritis. *Dig Dis Sci* 2007; **52**: 411-417 [PMID: 17195120]

91 **D'Elios MM**, Appelmelk BJ, Amedei A, Bergman MP, Del Prete G. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. *Trends Mol Med* 2004; **10**: 316-323 [PMID: 15242679]

92 **Amedei A**, Munari F, Bella CD, Niccolai E, Benagiano M, Bencini L, Cianchi F, Farsi M, Emmi G, Zanotti G, de Bernard M, Kundu M, D'Elios MM. Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma. *Intern Emerg Med* 2014; **9**: 303-309 [PMID: 23054412]

93 **Gareau MG**, Wine E, Rodrigues DM, Cho JH, Whary MT, Philpott DJ, Macqueen G, Sherman PM. Bacterial infection causes stress-induced memory dysfunction in mice. *Gut* 2011; **60**: 307-317 [PMID: 20966022 DOI: 10.1136/gut.2009.202515]

94 **Suzuki H**, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 168-174 [PMID: 23358394 DOI: 10.1038/nrgastro.2013.9]

95 **Chauhan A**, Mullins PA, Taylor G, Petch MC, Schofield PM. Cardioesophageal reflex: a mechanism for "linked angina" in patients with angiographically proven coronary artery disease. *J Am Coll Cardiol* 1996; **27**: 1621-1628 [PMID: 8636546]

96 **Akkaya N**, Akkaya S, Polat Y, Turk M, Turk T, Turhal E, Sahin F. Helicobacter pylori seropositivity in fibromyalgia syndrome. *Clin Rheumatol* 2011; **30**: 43-49 [PMID: 21120564]

97 **Lee YY**, Chua AS. Influence of gut microbes on the brain-gut axis (Gut 2011; 60: 307-317). *J Neurogastroenterol Motil* 2011; **17**: 427-429 [PMID: 22148116 DOI: 10.5056/jnm.2011.17.4.427]

98 **Collins SM**, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. *Nat Rev Microbiol* 2012; **10**: 735-742 [PMID: 23000955 DOI: 10.1038/nrmicro2876]

99 **Foster JA**, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. *Trends Neurosci* 2013; **36**: 305-312 [PMID: 23384445 DOI: 10.1016/j.tins.2013.01.005]

100 **Yang YJ**, Sheu BS. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. *Helicobacter* 2012; **17**: 297-304 [PMID: 22759330 DOI: 10.1111/j.1523-5378.2012.00941.x]

101 **Yang YJ**, Sheu BS, Yang HB, Lu CC, Chuang CC. Eradication of Helicobacter pylori increases childhood growth and serum acylated ghrelin levels. *World J Gastroenterol* 2012; **18**: 2674-2681 [PMID: 22690077 DOI: 10.3748/wjg.v18.i21.2674]

102 **Francois F**, Roper J, Joseph N, Pei Z, Chhada A, Shak JR, de Perez AZ, Perez-Perez GI, Blaser MJ. The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. *BMC Gastroenterol* 2011; **11**: 37 [PMID: 21489301 DOI: 10.1186/1471-230X-11-37]

103 **Deng ZH**, Chu B, Xu YZ, Zhang B, Jiang LR. Influence of Helicobacter pylori infection on ghrelin levels in children. *World J Gastroenterol* 2012; **18**: 5096-5100 [PMID: 23049220 DOI: 10.3748/wjg.v18.i36.5096]

104 **Tatsuguchi A**, Miyake K, Gudis K, Futagami S, Tsukui T, Wada K, Kishida T, Fukuda Y, Sugisaki Y, Sakamoto C. Effect of Helicobacter pylori infection on ghrelin expression in human gastric mucosa. *Am J Gastroenterol* 2004; **99**: 2121-2127 [PMID: 15554990]

105 **Weigt J**, Malfertheiner P. Influence of Helicobacter pylori on gastric regulation of food intake. *Curr Opin Clin Nutr Metab Care* 2009; **12**: 522-525 [PMID: 19584718 DOI: 10.1097/MCO.0b013e32832eb56e]

106 **Roper J**, Francois F, Shue PL, Mourad MS, Pei Z, Olivares de Perez AZ, Perez-Perez GI, Tseng CH, Blaser MJ. Leptin and ghrelin in relation to Helicobacter pylori status in adult males. *J Clin Endocrinol Metab* 2008; **93**: 2350-2357 [PMID: 18397989 DOI: 10.1210/jc.2007-2057]

107 **Jang EJ**, Park SW, Park JS, Park SJ, Hahm KB, Paik SY, Sin MK, Lee ES, Oh SW, Park CY, Baik HW. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. *J Gastroenterol Hepatol* 2008; **23** Suppl 2: S278-S285 [PMID: 19120912 DOI: 10.1111/j.1440-1746.2008.05415.x]

108 **Osawa H**, Kita H, Ohnishi H, Nakazato M, Date Y, Bowlus CL, Ishino Y, Watanabe E, Shiiya T, Ueno H, Hoshino H, Satoh K, Sugano K. Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. *J Gastroenterol* 2006; **41**: 954-961 [PMID: 17096064]

109 **Choe YH**, Lee JH, Lee HJ, Paik KH, Jin DK, Song SY, Lee JH. Ghrelin Levels in Gastric Mucosa before and after Eradication of Helicobacter pylori. *Gut Liver* 2007; **1**: 132-137 [PMID: 20485629 DOI: 10.5009/gnl.2007.1.2.132]

110 **Abdullahi M**, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J, Leonetti F, Severi C. The eradication of Helicobacter pylori is affected by body mass index (BMI). *Obes Surg* 2008; **18**: 1450-1454 [PMID: 18443890 DOI: 10.1007/s11695-008-9477-z]

111 **Ünal HÜ**, Akin E, Aydin İ, Korkmaz M, Özel S, Selçuk H, Yilmaz U. Ongoing symptoms after eradication of Helicobacter pylori: psychiatric disorders may accompany. *Turk J Gastroenterol* 2013; **24**: 15-21 [PMID: 23794339]

112 **Kotan Z**, Sarandöl E, Kırhan E, Ozkaya G, Kırlı S. Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features. *Ther Adv Psychopharmacol* 2012; **2**: 65-74 [PMID: 23983958 DOI: 10.1177/2045125312436572]

113 **Winston JH**, Sarna SK. Developmental origins of functional dyspepsia-like gastric hypersensitivity in rats. *Gastroenterology* 2013; **144**: 570-579.e3 [PMID: 23142231 DOI: 10.1053/j.gastro.2012.11.001]

114 **Bhide AA**, Cartwright R, Khullar V, Digesu GA. Biomarkers in overactive bladder. *Int Urogynecol J* 2013; **24**: 1065-1072 [PMID: 23314226 DOI: 10.1007/s00192-012-2027-1]

115 **Beydoun MA**, Beydoun HA, Shroff MR, Kitner-Triolo MH, Zonderman AB. Helicobacter pylori seropositivity and cognitive performance among US adults: evidence from a large national survey. *Psychosom Med* 2013; **75**: 486-496 [PMID: 23697465 DOI: 10.1097/PSY.0b013e31829108c3]

116 **Agrawal A**, Gupta A, Chandra M, Koowar S. Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. *Indian J Gastroenterol* 2011; **30**: 29-32 [PMID: 21416318 DOI: 10.1007/s12664-011-0087-7]

117 **Roubaud Baudron C**, Letenneur L, Langlais A, Buissonnière A, Mégraud F, Dartigues JF, Salles N. Does Helicobacter pylori infection increase incidence of dementia? The Personnes Agées QUID Study. *J Am Geriatr Soc* 2013; **61**: 74-78 [PMID: 23252507 DOI: 10.1111/jgs.12065]

118 **Muhsen K**, Ornoy A, Akawi A, Alpert G, Cohen D. An association between Helicobacter pylori infection and cognitive function in children at early school age: a community-based study. *BMC Pediatr* 2011; **11**: 43 [PMID: 21612616 DOI: 10.1186/1471-2431-11-43]

119 **Ozdemir V**, Jamal MM, Osapay K, Jadus MR, Sandor Z, Hashemzadeh M, Szabo S. Cosegregation of gastrointestinal ulcers and schizophrenia in a large national inpatient discharge database: revisiting the "brain-gut axis" hypothesis in ulcer pathogenesis. *J Investig Med* 2007; **55**: 315-320 [PMID: 17963681]

120 **Dylag K**, Hubalewska-Mazgaj M, Surmiak M, Szmyd J, Brzozowski T. Probiotics in the mechanism of protection against gut inflammation and therapy of gastrointestinal disorders. *Curr Pharm Des* 2014; **20**: 1149-1155 [PMID: 23755726]

121 **Nada T**, Nomura M, Iga A, Kawaguchi R, Ochi Y, Saito K, Nakaya Y, Ito S. Autonomic nervous function in patients with peptic ulcer studied by spectral analysis of heart rate variability. *J Med* 2001; **32**: 333-347 [PMID: 11958279]

122 **Lugon JR**, Moreira MD, de Almeida JM, Silva AS, Esberard EC, Bousquet-Santos K, Carvalho AG, Mendes LC, da Nobrega AC. Cardiovascular autonomic response to food ingestion in patients with gastritis: a comparison between Helicobacter pylori-positive and -negative patients. *Helicobacter* 2006; **11**: 173-180 [PMID: 16684265]

123 **Stanghellini V**, Barbara G, de Giorgio R, Tosetti C, Cogliandro R, Cogliandro L, Salvioli B, Corinaldesi R. Review article: Helicobacter pylori, mucosal inflammation and symptom perception--new insights into an old hypothesis. *Aliment Pharmacol Ther* 2001; **15** Suppl 1: 28-32 [PMID: 11488659]

124 **Thor PJ**, Błaut U. Helicobacter pylori infection in pathogenesis of gastroesophageal reflux disease. *J Physiol Pharmacol* 2006; **57** Suppl 3: 81-90 [PMID: 17033107]

125 **Shahabi S**, Rasmi Y, Jazani NH, Hassan ZM. Protective effects of Helicobacter pylori against gastroesophageal reflux disease may be due to a neuroimmunological anti-inflammatory mechanism. *Immunol Cell Biol* 2008; **86**: 175-178 [PMID: 17923849]

126 **Mönnikes H**, van der Voort IR, Wollenberg B, Heymann-Monnikes I, Tebbe JJ, Alt W, Arnold R, Klapp BF, Wiedenmann B, McGregor GP. Gastric perception thresholds are low and sensory neuropeptide levels high in helicobacter pylori-positive functional dyspepsia. *Digestion* 2005; **71**: 111-123 [PMID: 15785037]

127 **Moayyedi P**, Soo S, Deeks JJ, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D. WITHDRAWN: Eradication of Helicobacter pylori for non-ulcer dyspepsia. *Cochrane Database Syst Rev* 2011; (**2**): CD002096 [PMID: 21328254 DOI: 10.1002/14651858.CD002096.pub5]

128 **Mearin F**, de Ribot X, Balboa A, Salas A, Varas MJ, Cucala M, Bartolomé R, Armengol JR, Malagelada JR. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia? *Gut* 1995; **37**: 47-51 [PMID: 7672680]

129 **Danesh J**, Lawrence M, Murphy M, Roberts S, Collins R. Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. *Arch Intern Med* 2000; **160**: 1192-1198 [PMID: 10789614]

130 **McColl K**, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, Kelman A, Penny C, Knill-Jones R, Hilditch T. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. *N Engl J Med* 1998; **339**: 1869-1874 [PMID: 9862941]

131 **Laine L**, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. *Ann Intern Med* 2001; **134**: 361-369 [PMID: 11242496]

132 **Pirtniecks A**, Smith LF, Thorpe JA. Autonomic dysfunction in non-specific disorders of oesophageal motility. *Eur J Cardiothorac Surg* 2000; **17**: 101-105 [PMID: 10731643]

133 **Futagami S**, Shimpuku M, Yin Y, Shindo T, Kodaka Y, Nagoya H, Nakazawa S, Fujimoto M, Izumi N, Ohishi N, Kawagoe T, Horie A, Iwakiri K, Sakamoto C. Pathophysiology of functional dyspepsia. *J Nippon Med Sch* 2011; **78**: 280-285 [PMID: 22041874]

134 **Tillisch K**, Mayer EA, Labus JS, Stains J, Chang L, Naliboff BD. Sex specific alterations in autonomic function among patients with irritable bowel syndrome. *Gut* 2005; **54**: 1396-1401 [PMID: 15923667]

135 **Miyaji H**, Azuma T, Ito S, Abe Y, Ono H, Suto H, Ito Y, Yamazaki Y, Kohli Y, Kuriyama M. The effect of helicobacter pylori eradication therapy on gastric antral myoelectrical activity and gastric emptying in patients with non-ulcer dyspepsia. *Aliment Pharmacol Ther* 1999; **13**: 1473-1480 [PMID: 10571604]

136 **Ghoshal UC**, Chourasia D. Gastroesophageal Reflux Disease and Helicobacter pylori: What May Be the Relationship? *J Neurogastroenterol Motil* 2010; **16**: 243-250 [PMID: 20680162 DOI: 10.5056/jnm.2010.16.3.243]

137 **Schenk BE**, Kuipers EJ, Klinkenberg-Knol EC, Bloemena E, Nelis GF, Festen HP, Jansen EH, Biemond I, Lamers CB, Meuwissen SG. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. *Aliment Pharmacol Ther* 1998; **12**: 605-612 [PMID: 9701523]

138 **Zub-Pokrowiecka A**, Rembiasz K, Konturek SJ, Budzynski A, Konturek PC, Budzynski P. Ghrelin in diseases of the gastric mucosa associated with Helicobacter pylori infection. *Med Sci Monit* 2010; **16**: CR493-CR500 [PMID: 20885354]

139 **Konturek JW**, Stoll R, Menzel J, Konturek M, Konturek SJ, Domschke W. Eradication of Helicobacter pylori restores the inhibitory effect of cholecystokinin on gastric motility in duodenal ulcer patients. *Scand J Gastroenterol* 2001; **36**: 241-246 [PMID: 11305509]

140 **Chiloiro M**, Russo F, Riezzo G, Leoci C, Clemente C, Messa C, Di Leo A. Effect of Helicobacter pylori infection on gastric emptying and gastrointestinal hormones in dyspeptic and healthy subjects. *Dig Dis Sci* 2001; **46**: 46-53 [PMID: 11270793]

141 **Tsai SH**, Chen CM, Chang CS, Chen GH. Effect of Helicobacter pylori infection on intragastric acidity in patients with reflux esophagitis. *J Gastroenterol* 2004; **39**: 821-826 [PMID: 15565399]

142 **Zerbib F**, Bicheler V, Leray V, Joubert M, Bruley des Varannes S, Galmiche JP. H. pylori and transient lower esophageal sphincter relaxations induced by gastric distension in healthy humans. *Am J Physiol Gastrointest Liver Physiol* 2001;

281: G350-G356 [PMID: 11447014]

143 **Tanaka I**, Tatsumi Y, Kodama T, Kato K, Fujita S, Mitsufuji S, Kashima K. Effect of Helicobacter pylori eradication on gastroesophageal function. *J Gastroenterol Hepatol* 2004; **19**: 251-257 [PMID: 14748870]

144 **Sarnelli G**, Cuomo R, Janssens J, Tack J. Symptom patterns and pathophysiological mechanisms in dyspeptic patients with and without Helicobacter pylori. *Dig Dis Sci* 2003; **48**: 2229-2236 [PMID: 14714606]

145 **Thumshirn M**, Camilleri M, Saslow SB, Williams DE, Burton DD, Hanson RB. Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. *Gut* 1999; **44**: 55-64 [PMID: 9862826]

146 **Koskenpato J**, Korppi-Tommola T, Kairemo K, Färkkilä M. Long-term follow-up study of gastric emptying and Helicobacter pylori eradication among patients with functional dyspepsia. *Dig Dis Sci* 2000; **45**: 1763-1768 [PMID: 11052317]

147 **Lin Z**, Chen JD, Parolisi S, Shifflett J, Peura DA, McCallum RW. Prevalence of gastric myoelectrical abnormalities in patients with nonulcer dyspepsia and H. pylori infection: resolution after H. pylori eradication. *Dig Dis Sci* 2001; **46**: 739-745 [PMID: 11330406]

148 **Thor P**, Lorens K, Tabor S, Herman R, Konturek JW, Konturek SJ. Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia. *J Physiol Pharmacol* 1996; **47**: 469-476 [PMID: 8877902]

149 **Manes G**, Esposito P, Lioniello M, Bove A, Mosca S, Balzano A. Manometric and pH-metric features in gastro-oesophageal reflux disease patients with and without Helicobacter pylori infection. *Dig Liver Dis* 2000; **32**: 372-377 [PMID: 11030180]

150 **Giral A**, Celikel CA, Ozdogan O, Tözün N, Ulusoy NB, Kalayci C. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. *J Gastroenterol Hepatol* 2005; **20**: 1886-1891 [PMID: 16336449]

151 **Ando T**, El-Omar EM, Goto Y, Nobata K, Watanabe O, Maeda O, Ishiguro K, Minami M, Hamajima N, Goto H. Interleukin 1B proinflammatory genotypes protect against gastro-oesophageal reflux disease through induction of corpus atrophy. *Gut* 2006; **55**: 158-164 [PMID: 16120761]

152 **Iijima K**, Ohara S, Sekine H, Koike T, Kato K, Asaki S, Shimosegawa T, Toyota T. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. *Gut* 2000; **46**: 20-26 [PMID: 10601049]

153 **Konturek SJ**, Brzozowski T, Konturek PC, Schubert ML, Pawlik WW, Padol S, Bayner J. Brain-gut and appetite regulating hormones in the control of gastric secretion and mucosal protection. *J Physiol Pharmacol* 2008; **59** Suppl 2: 7-31 [PMID: 18812626]

百世登

Baishideng®

9 771007 932045

18>